Disseminated on behalf of Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) and may include paid advertising.
- As precision oncology becomes increasingly dependent on biomarker-driven therapies, smarter clinical trial design, and advanced drug delivery technologies, companies capable of integrating may be better positioned to address some of oncology’s most persistent development challenges.
- Onco-Innovations pairs a PNKP inhibitor, a DDR target distinct from PARP, with a nanoparticle delivery system in its lead candidate ONC010, and adds AI through its Inka Health subsidiary and the SynoGraph causal AI platform
- Onco-Innovations is advancing ONC010 through IND-enabling, manufacturing, and regulatory work, while using AI-enabled tools intended to support patient stratification, trial design, and evidence generation
Cancer drug development has three persistent problems. Tumors evolve resistance to therapies that once worked. Clinical trials fail often and cost enormously, frequently because the right patients are hard to identify. And many promising drugs never reach patients because they are too toxic or too difficult to deliver. For years, researchers attacked these problems separately. A newer approach treats them as connected, combining novel biology, advanced drug delivery, and artificial intelligence into a single development strategy. Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) is a company building at that intersection.
New Biology: Targeting DNA Repair Beyond PARP
Cancer treatments such as radiation and chemotherapy work by damaging tumor DNA. Cancer cells survive by repairing that damage, which is why DNA Damage Response (“DDR”) inhibitors have become one of oncology’s fastest-moving categories. PARP inhibitors opened the field, but newer targets are expanding it. Onco-Innovations focuses on Polynucleotide Kinase Phosphatase, or PNKP, an enzyme central to repairing DNA strand breaks.
Researchers are investigating PNKP inhibition through two complementary mechanisms. It sensitizes cancer cells to radiation and DNA-damaging chemotherapies, and it may produce antitumor activity as a monotherapy through synthetic lethality, in tumors that already carry specific repair deficiencies such as PTEN or SHP-1 loss. In preclinical work, PNKP inhibition has shown activity across colorectal, lung, breast, prostate, and ovarian cancers, as well as lymphoma and leukemia. Company materials describe DDR inhibitors as more than $7 billion in global sales in 2025, with PNKP positioned as an emerging class distinct from PARP.
Better Delivery: Widening the Safety Window
New biology only helps if the drug reaches the tumor. Many DDR inhibitors have struggled with off-target toxicity or poor solubility that complicates dosing. Onco’s lead candidate, ONC010, addresses that directly. It pairs A83B4C63, a small-molecule PNKP inhibitor, with a polymer micelle carrier designed to solubilize the drug, extend its time in circulation, increase tumor accumulation, and limit exposure to healthy tissue. In this design, the nanoparticle is not packaging; it is part of the therapy.
In animal studies, the formulation slowed tumor growth, improved survival, and showed a favorable toxicity profile while increasing sensitivity to radiation and certain chemotherapies. The same delivery platform is designed to carry other hydrophobic, hard-to-deliver drugs, which the company views as a broader pipeline opportunity.
Smarter Development: Causal AI for Patients and Trials
The third front is where a drug’s path to approval is decided. Oncology trials are among the most expensive and failure-prone in medicine, and better patient selection is one of the few levers shown to improve their odds. Onco-Innovations acquired Inka Health in 2025 and, with it, SynoGraph, a causal AI prototype platform the company says is being designed to integrate real-world data, clinical evidence, and molecular insights to model treatment outcomes, safety, adverse events, and clinical trial performance.
Because regulators and clinicians remain wary of opaque systems, the platform is intended to support more transparent, auditable reasoning than conventional black-box models. The intent is practical: identify which patients are most likely to respond, design trials around them, and generate supporting evidence. Through Inka Health, the company has announced research collaborations and initiatives involving organizations including AstraZeneca and GSK.
Where the Three Meet
Individually, each of these advances is meaningful. Their potential value lies in how they interact. A more selective DNA-repair target reaches the tumor through a delivery system built for it, while AI helps choose the patients most likely to benefit and shapes the trials that test them. That is the logic behind Onco-Innovations’ dual platform, uniting DDR-targeted therapeutics with AI-driven precision oncology, and it aims squarely at the cancers that resist conventional treatment. The approach is designed to reduce development risk and shorten timelines, though, as with any preclinical program, those benefits remain to be proven in the clinic.
Building Toward First-in-Human
Onco-Innovations are preclinical and advancing toward first-in-human studies. It is running IND-enabling work with contract partners including Dalton Pharma Services and Nucro-Technics, and has established an Australian subsidiary to support planned Phase I activity through that country’s regulatory pathway. The scientific bench behind the program includes researchers involved in foundational PNKP-inhibitor work and development of the nanoparticle delivery mechanism.
Cancer rarely yields to a single idea. The more durable progress tends to come from combining them, matching the right target to the right delivery system and the right patients. Whether Onco-Innovations converts that convergence into clinical success remains to be seen, but the strategy reflects where oncology drug development is increasingly headed.
For more information, visit https://oncoinnovations.com.
NOTE TO INVESTORS: The latest news and updates relating to ONNVF are available in the company’s newsroom at ibn.fm/ONNVF
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
